Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy

Circulation Journal

Volumn 75, Issue 4, 2011, Pages 919-926

  Kubo, Toru ^a   Kitaoka, Hiroaki ^a   Okawa, Makoto ^a   Yamanaka, Shigeo ^a   Hirota, Takayoshi ^a   Baba, Yuichi ^a   Hayato, Kayo ^a   Yamasaki, Naohito ^a   Matsumura, Yoshihisa ^a   Yasuda, Nobufumi ^a   Sugiura, Tetsuro ^a   Doi, Yoshinori L ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Biomarkers; Hypertrophic cardiomyopathy; Plasma BNP; Serum cardiac troponin I

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; TROPONIN I;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BRAIN EMBOLISM; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; SCHOOL CHILD;

AGED; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; EMBOLISM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; RETROSPECTIVE STUDIES; STROKE; TACHYCARDIA, VENTRICULAR; TROPONIN I;

EID: 79953672659     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0782     Document Type: Article

References (25)

1. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-785.
2. Maron BJ. Hypertrophic cardiomyopathy: A systematic review. JAMA 2002; 287: 1308-1320.
3. Kimura A. Molecular etiology and pathogenesis of hypertrophic cardiomyopathy. Circ J 2008; 72(Suppl A): A-38-A-48.
4. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778-1785.
5. Elliott PM, Gimeno BJ, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357: 420-424.
6. Leonardi S, Raineri C, De Ferrari GM, Ghio S, Scelsi L, Pasotti M, et al. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009; 30: 2003-2010.
7. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: Clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995; 26: 1529-1536.
8. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-655.
9. Kofflard MJM, Ten Cate FJ, van der Lee C, van Domberg RT. Hypertrophic cardiomyopathy in a large community-based population: Clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003; 41: 987-993.
10. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, et al. Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral-based patient population. Circulation 2000; 102: 858-864.
11. Nasermoaddeli A, Miura K, Matsumori A, Soyama Y, Morikawa Y, Kitabatake A, et al. Prognosis and prognostic factors in patients with hypertrophic cardiomyopathy in Japan: Results from a nationwide survey. Heart 2007; 93: 711-715.
12. Kubo T, Kitaoka H, Okawa M, Hirota T, Hayato K, Yamasaki N, et al. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy: Results from Kochi RYOMA Study. Circ J 2009; 73: 1599-1605.
13. Kitaoka H, Kubo T, Okawa M, Hayato K, Yamasaki N, Matsumura Y, et al. Impact of metalloproteinases on left ventricular remodeling and heart failure events in patients with hypertrophic cardiomyopathy. Circ J 2010; 74: 1191-1196.
14. Nakamura T, Sakamoto K, Yamano T, Kikkawa M, Zen K, Hikosaka T, et al. Increased plasma brain natiuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39: 1657-1663.
15. Maron BJ, Tholakanahalli VN, Zenovich AG, Casey SA, Duprez D, Aeppli DM, et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 2004; 109: 984-989.
16. Takeuchi I, Inomata T, Nishii M, Koitabashi T, Nakano H, Shinagawa H, et al. Clinical characteristics of heart disease patients with a good prognosis in spite of markedly increased plasma levels of type-B natriuretic peptide (BNP): Anomalous behavior of plasma BNP in hypertrophic cardiomyopathy. Circ J 2005; 69: 277-282.
17. Mutlu B, Bayrak F, Kahveci G, Degertekin M, Eroglu E, Basaran Y. Usufulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy. Am J Cardiol 2006; 98: 1504-1506.
18. Thaman R, Esteban MT, Barnes S, Gimeno JR, Mist B, Murphy R, et al. Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 2006; 98: 515-519.
19. Pieroni M, Bellocci F, Sanna T, Verardo R, Ierardi C, Maseri A, et al. Increased brain natriuretic peptide secretion is a marker of disease progression in nonobstructive hypertrophic cardiomyopathy. J Cardiac Fail 2007; 13: 380-398.
20. Kubo T, Kitaoka H, Okawa M, Yamanaka S, Hirota T, Hoshikawa E, et al. Serum cardiac troponin I is related to increased left ventricular wall thickness, left ventricular dysfunction and male gender in hypertrophic cardiomyopathy. Clin Cardiol 2010; 10: 9-16.
21. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104: 2517-2524.
22. Maron BJ, Olivotto I, Bellone P, Rosa Conte M, Cecchi F, Flygenring BP, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39: 301-307.
23. Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, Okada H, et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103: 369-374.
24. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108: 833-838.
25. Taniguchi R, Sato Y, Yamada T, Ooba M, Higuchi H, Matsumori A, et al. Combined measurements of cardiac troponin T and N-terminal Pro-brain natriuretic peptide in patients with heart failure. Circ J 2004; 68: 1160-1164.